title: [Use of statins for preventing cardiovascular and renal outcomes in patients with chronic kidney disease excluding dialysis: guideline from the Italian Society of Nephrology].
abstract: BACKGROUND
  The current 3rd edition of the Italian Society of Nephrology guidelines has been drawn up to summarize evidence of key intervention issues on the basis of systematic reviews (SR) of randomized trials (RCT) or RCT data only. In the present guideline, evidence of the efficacy of statins in chronic kidney disease patients (CKD, non-dialysis patients) is presented.
  
  
  METHODS
  SR of RCT and RCT on statins in CKD (non-dialysis) patients were identified referring to a Cochrane Library and Renal Health Library search (2005 update). Quality of SR and RCT was assessed according to current methodological standards.
  
  
  RESULTS
  Three SR and 36 RCT were found addressing this intervention issue. Methodological quality of the relevant RCT was suboptimal. There is no enough evidence to suggest that statins are associated with a significant reduction in the risk of serum creatinine doubling or of end-stage renal disease in CKD patients (evidence from SR and RCT). Statins compared to placebo or no treatment are associated with significant improvements in proteinuria (evidence from SR). Statins are also associated with significant reduction in the risk of cardiovascular events and mortality in CKD patients (evidence from SR and RCT) and in renal transplant recipients (evidence from RCT), and no significant increases in the risk of rhabdomyolysis and hepatotoxicity in CKD patients.
  
  
  CONCLUSIONS
  Available evidence supports the hypothesis that statins should be recommended in CKD patients (non-dialysis patients) on the basis of significant evidence of cardiac and renal protection and no evidence of significant harms. Further studies are necessary to test this hypothesis in selected patient populations.
authors.affiliation: Italian Society of Nephrology - Italy.
authors.forename: L
authors.initials: L
authors.lastname: De Nicola
authors.forename: G F M
authors.initials: GF
authors.lastname: Strippoli
authors.forename: P
authors.initials: P
authors.lastname: Ravani
authors.forename: L
authors.initials: L
authors.lastname: Del Vecchio
authors.forename: B
authors.initials: B
authors.lastname: Cianciaruso
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000517:prevention & control*; D051436:Renal Insufficiency, Chronic / Q000150:complications
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors